Palonosetron

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 22 USDMF, 3 JDMF, 8 EU WC, 4 KDMF, 14 NDC API, 24 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

12 Drugs in Development

12 Drugs in Development

INTERMEDIATES

11 Intermediate Suppliers

11 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

84 FDF Dossiers, 34 FDA Orange Book, 20 Europe, 2 Canada, 6 Australia, 1 South Africa, 21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE, SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML), POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL, SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML), INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 2 Rochem International Inc, 16 SPI Pharma, 7 DKSH, 3 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 6 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Pramukh Pharmachem, 4 ACG Worldwide, 6 Actylis, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 3 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 6 Kerry, 3 Lonza Capsugel, 9 Microlex e.U, 1 NEWEDGE Overseas, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 22 Roquette, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

47 Fillers, Diluents & Binders, 20 Disintegrants & Superdisintegrants, 18 Direct Compression, 17 Lubricants & Glidants, 16 Thickeners and Stabilizers, 15 Taste Masking, 15 Chewable & Orodispersible Aids, 12 Parenteral, 12 Co-Processed Excipients, 11 Coating Systems & Additives, 11 Film Formers & Plasticizers, 10 Granulation, 8 Empty Capsules, 6 Controlled & Modified Release, 3 Solubilizers, 3 Emulsifying Agents, 2 Coloring Agents, 2 Topical, 2 Rheology Modifiers, 2 API Stability Enhancers, 1 Soft Gelatin

DIGITAL CONTENT

62 NEWS #PharmaBuzz

62 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 18 Finished Drug Prices, 10 Annual Reports

MARKET PLACE

8 APIs, 6 FDF Dossiers

PATENTS & EXCLUSIVITIES

76 US Patents, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

7 USP, 7 Others

$ Xls

Filters

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Avenacy Launches Palonosetron Hydrochloride Injection In US Market

22 Jul 2024

// BUSINESSWIRE

Helsinn Group launches Akynzeo injection in US market

26 Jun 2024

// PHARMABIZ

Helsinn & Chugai sign a partnership agreement renewal to commercialize AKYNZEO

12 Jun 2024

// GLOBENEWSWIRE

Nanjing King's Generic Palonosetron Hydrochloride Receives Approval in the U.S.

14 Aug 2023

// FDA

Helsinn announces publication of data evaluating impact of AKYNZEO

12 Jun 2023

// GLOBENEWSWIRE

Glenmark introduces medication to prevent chemotherapy-induced nausea

23 Jan 2023

// ECONOMIC TIMES

Palonosetron

Palonosetron

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers

22 USDMF

3 JDMF

8 EU WC

4 KDMF

14 NDC API

24 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

12 Drugs in Development

INTERMEDIATES

11 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

84 FDF Dossiers

34 FDA Orange Book

20 Europe

2 Canada

6 Australia

1 South Africa

21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE

SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL

SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)

INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

2 Rochem International Inc

16 SPI Pharma

7 DKSH

3 Faran Shimi Pharmaceutical

3 Boai NKY Pharmaceuticals Ltd

1 Chynops Pharma

6 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 Pramukh Pharmachem

4 ACG Worldwide

6 Actylis

1 Alcedo Pharmachem

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 BASF

3 DFE Pharma

5 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

2 Ingredion Pharma Solutions

6 Kerry

3 Lonza Capsugel

9 Microlex e.U

1 NEWEDGE Overseas

2 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qualicaps

22 Roquette

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

9 Sigachi Industries

1 Ulanqab Kema New Material

3 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

47 Fillers, Diluents & Binders

20 Disintegrants & Superdisintegrants

18 Direct Compression

17 Lubricants & Glidants

16 Thickeners and Stabilizers

15 Taste Masking

INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 0.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons